Table 4.
Antimicrobial treatment regimen for 210 patients with Elizabethkingia spp. infection.
| Antibiotics | Total (n = 210) |
Survivor (n = 157) |
Non-survivor (n = 53) |
p-Value |
|---|---|---|---|---|
| Prolonged antibiotics use (%) | 177 (84.3) | 129 (82.2) | 48 (90.6) | 0.146 |
| Appropriate antibiotic therapy (%) | 92 (44.2) | 70 (45.2) | 22 (41.5) | 0.644 |
| Antibiotics therapy | 0.803 | |||
| Monotherapy | 23 (11.0) | 18 (11.5) | 5 (9.4) | |
| Combination therapy | 187 (89.0) | 139 (88.5) | 48 (90.6) | |
| Antibiotics regimen | ||||
| Monotherapy | ||||
| Glycopeptide | 127 (60.5) | 97 (61.8) | 30 (56.6) | 0.505 |
| Carbapenem | 124 (59.0) | 90 (57.3) | 34 (64.2) | 0.382 |
| Fluroquinolone | 69 (32.9) | 51 (32.5) | 18 (34.0) | 0.843 |
| Cephalosporin | 54 (25.7) | 39 (24.8) | 15 (28.3) | 0.618 |
| Colistin | 54 (25.7) | 36 (22.9) | 18 (34.0) | 0.112 |
| Anti-pseudomonal penicillin | 37 (17.6) | 30 (19.1) | 7 (13.2) | 0.330 |
| Cotrimoxazole | 34 (16.2) | 22 (14.0) | 12 (22.6) | 0.140 |
| Aminoglycoside | 16 (7.6) | 10 (6.4) | 6 (11.3) | 0.242 |
| Combination therapy | ||||
| Carbapenem+glycopeptide | 94 (44.8) | 72 (45.9) | 22 (41.5) | 0.582 |
| Carbapenem+colistin | 39 (18.6) | 26 (16.6) | 13 (24.5) | 0.197 |
| Fluroquinolone+glycopeptide | 39 (18.6) | 28 (17.8) | 11 (20.8) | 0.636 |
| Anti-pseudomonal penicillin+glycopeptide | 22 (10.5) | 20 (12.7) | 2 (3.8) | 0.045 |
| Anti-pseudomonal penicillin+fluroquinolone | 10 (4.8) | 8 (5.1) | 2 (3.8) | >0.999 |
| Carbapenem+aminoglycoside | 9 (4.3) | 6 (3.8) | 3 (5.7) | 0.695 |
Categorical variables are shown as numbers (percentage).